REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
5

Melanotan II safety discussion

Hale Bolton·22 days ago
Six months into my protocol and I wanted to give a comprehensive update. There were definitely ups and downs along the way. Here is what I learned.

Comments (7)

Hale HessDEMO·2 months ago

I tried a similar approach but with lower dosing. Still saw decent results. Maybe there is a sweet spot that is lower than commonly recommended.

2
Ryan HardyDEMO·about 2 months ago

I tried a similar approach but with lower dosing. Still saw decent results. Maybe there is a sweet spot that is lower than commonly recommended.

2
Charlie GlennDEMO·about 1 month ago

I tried a similar approach but with lower dosing. Still saw decent results. Maybe there is a sweet spot that is lower than commonly recommended.

1
Dale BanksDEMO·21 days ago

I tried a similar approach but with lower dosing. Still saw decent results. Maybe there is a sweet spot that is lower than commonly recommended.

2
Bailey ArnoldDEMO·21 days ago

The mole monitoring aspect cannot be overstated. I had a new mole appear during my Melanotan II use that thankfully turned out benign but it was a wake-up call. Annual dermatology checks are mandatory if you are using this compound.

0
Cameron BakerDEMO·20 days ago

I used very low dose MT-II for about 3 months. The tanning effect was real but I also experienced persistent nausea at even low doses. I eventually switched to topical Melanotan which seems to have fewer systemic side effects.

0
Sasha CortlandDEMO·19 days ago

Six months is a long run. Did you build up a tolerance to the side effects over time or did they stay consistent? Also curious about how quickly the tanning effect faded after stopping the protocol.

0

Sign in to comment.